Dr. Arjun Goyal is a co-founder and managing director of Vida Ventures. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Pionyr Immunotherapeutics and has been involved in Vida Venture’s investments in Homology Medicines (NASDAQ: FIXX), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios BioPharmaceutical (acquired by Bayer). Before co-founding Vida Ventures, Arjun was a life sciences investor at 5AM Ventures.
Arjun received his BS in medical science, diploma in French, and his MD degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in internal medicine in Sydney. He received his MPhil in Bioscience Enterprise from the University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work, including the American Australian Association Education Fellowship, Robert Kaplan HBS Life Science Fellowship, Oxford Clarendon Scholarship, Commonwealth Scholarship, and Gates Cambridge Scholarship.
He is a co-inventor on one patent and has served on the editorial board of an international scientific journal. He serves on the Committee for the American Australian Association Education Fellowship.
